The Board of Directors of In5 has officially welcomed US-based emerging biotech company InSitu Biologics into the In5 Incubator, the largest hub for startups and entrepreneurs in UAE.
In5 is one of the leading incubators in the UAE, specializing in assisting tech, media and design startups. Their goal is to further enhance the Middle East’s strong investment environment by increasing investor access to leading startups in its habitat. The incubator has supported more than 500 businesses since its inception nearly a decade ago.
Mr. Kevin Bassett, President, and CEO of InSitu Biologics stated that “This partnership will allow InSitu Biologics to advance our ability to conduct investigational and clinical studies internationally, as well as secure funding and build important partnerships in the region.”
InSitu Biologics had attended the Arab Health 2022 Conference last month. Apart from that, at the upcoming Advance Health Event, InSitu Biologics will be presented as the first Health Partner Company of In5 – “The Future of Biotech R&D in the UAE.”
InSitu Biologics is an emerging biotech company currently conducting investigational pre-clinical work. The firm is focused on the development of a multi-phase prolonged-release drug delivery platform for localized treatment of pain, cancer, and infection.
The Company uses disruptive technology to address unmet needs in the pain management and drug delivery markets.